Your browser doesn't support javascript.
loading
Addiction Research Consortium: Losing and regaining control over drug intake (ReCoDe)-From trajectories to mechanisms and interventions.
Heinz, Andreas; Kiefer, Falk; Smolka, Michael N; Endrass, Tanja; Beste, Christian; Beck, Anne; Liu, Shuyan; Genauck, Alexander; Romund, Lydia; Banaschewski, Tobias; Bermpohl, Felix; Deserno, Lorenz; Dolan, Raymond J; Durstewitz, Daniel; Ebner-Priemer, Ulrich; Flor, Herta; Hansson, Anita C; Heim, Christine; Hermann, Derik; Kiebel, Stefan; Kirsch, Peter; Kirschbaum, Clemens; Koppe, Georgia; Marxen, Michael; Meyer-Lindenberg, Andreas; Nagel, Wolfgang E; Noori, Hamid R; Pilhatsch, Maximilian; Priller, Josef; Rietschel, Marcella; Romanczuk-Seiferth, Nina; Schlagenhauf, Florian; Sommer, Wolfgang H; Stallkamp, Jan; Ströhle, Andreas; Stock, Ann-Kathrin; Winterer, Georg; Winter, Christine; Walter, Henrik; Witt, Stephanie; Vollstädt-Klein, Sabine; Rapp, Michael A; Tost, Heike; Spanagel, Rainer.
Afiliação
  • Heinz A; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Kiefer F; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Smolka MN; Department of Psychiatry and Neuroimaging Centre, Technische Universität Dresden, Dresden, Germany.
  • Endrass T; Institute for Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.
  • Beste C; Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Technische Universität Dresden, Dresden, Germany.
  • Beck A; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Liu S; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Genauck A; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Romund L; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Banaschewski T; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Bermpohl F; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Deserno L; Department of Psychiatry and Neuroimaging Centre, Technische Universität Dresden, Dresden, Germany.
  • Dolan RJ; Max Planck Centre for Computational Psychiatry and Ageing Research & Wellcome Centre for Human Neuroimaging, University College London, London, UK.
  • Durstewitz D; Max Planck Centre for Computational Psychiatry and Ageing Research & Wellcome Centre for Human Neuroimaging, University College London, London, UK.
  • Ebner-Priemer U; Department of Theoretical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Flor H; Department of Sports and Sports Science, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany.
  • Hansson AC; Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Heim C; Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany.
  • Hermann D; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Kiebel S; Institute of Medical Psychology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Kirsch P; Department of Biobehavioral Health, Pennsylvania State University, University Park, Pennsylvania.
  • Kirschbaum C; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Koppe G; Feuerlein Center on Translational Addiction Medicine (FCTS), University of Heidelberg, Heidelberg, Germany.
  • Marxen M; Department of Psychiatry and Neuroimaging Centre, Technische Universität Dresden, Dresden, Germany.
  • Meyer-Lindenberg A; Department of Psychology and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.
  • Nagel WE; Department of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Noori HR; Department of Psychology, Biological Psychology, Technische Universität Dresden, Dresden, Germany.
  • Pilhatsch M; Department of Theoretical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Priller J; Department of Psychiatry and Neuroimaging Centre, Technische Universität Dresden, Dresden, Germany.
  • Rietschel M; Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Romanczuk-Seiferth N; Center for Information Services and High Performance Computing, Technische Universität Dresden, Dresden, Germany.
  • Schlagenhauf F; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Sommer WH; Max Planck Institute for Biological Cybernetics, Tübingen, Germany.
  • Stallkamp J; Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.
  • Ströhle A; Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Stock AK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.
  • Winterer G; Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Winter C; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Walter H; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Witt S; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Vollstädt-Klein S; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Rapp MA; Project Group for Automation in Medicine and Biotechnology, Fraunhofer IPA, Mannheim, Germany.
  • Tost H; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin (Campus Charité Mitte), Berlin, Germany.
  • Spanagel R; Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Technische Universität Dresden, Dresden, Germany.
Addict Biol ; 25(2): e12866, 2020 03.
Article em En | MEDLINE | ID: mdl-31859437
ABSTRACT
One of the major risk factors for global death and disability is alcohol, tobacco, and illicit drug use. While there is increasing knowledge with respect to individual factors promoting the initiation and maintenance of substance use disorders (SUDs), disease trajectories involved in losing and regaining control over drug intake (ReCoDe) are still not well described. Our newly formed German Collaborative Research Centre (CRC) on ReCoDe has an interdisciplinary approach funded by the German Research Foundation (DFG) with a 12-year perspective. The main goals of our research consortium are (i) to identify triggers and modifying factors that longitudinally modulate the trajectories of losing and regaining control over drug consumption in real life, (ii) to study underlying behavioral, cognitive, and neurobiological mechanisms, and (iii) to implicate mechanism-based interventions. These goals will be achieved by (i) using mobile health (m-health) tools to longitudinally monitor the effects of triggers (drug cues, stressors, and priming doses) and modify factors (eg, age, gender, physical activity, and cognitive control) on drug consumption patterns in real-life conditions and in animal models of addiction; (ii) the identification and computational modeling of key mechanisms mediating the effects of such triggers and modifying factors on goal-directed, habitual, and compulsive aspects of behavior from human studies and animal models; and (iii) developing and testing interventions that specifically target the underlying mechanisms for regaining control over drug intake.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Comportamental / Telemedicina / Transtornos Relacionados ao Uso de Substâncias / Sinais (Psicologia) / Pesquisa Biomédica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Comportamental / Telemedicina / Transtornos Relacionados ao Uso de Substâncias / Sinais (Psicologia) / Pesquisa Biomédica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article